Sofie Biosciences, Inc., the molecular imaging company specializing in novel tools for PET imaging and radiosynthesis of PET compounds, has announced the completion of the acquisition of Zevacor Pharma to form “Sofie.”
The addition of Zevacor Pharma’s 16 radiopharmacies and contract manufacturing organization will complement Sofie Biosciences’ imaging and radiochemistry product lines, bringing innovative technologies and theranostic production together under one company focused on the growth of molecular imaging and radioisotope-based therapeutics for clinical and preclinical use.
Zevacor Pharma, formerly known as IBA North America, annually serves over 425,000 patients and 700+ clinical practices. Patrick Phelps, President and CEO of SOFIE remarked: “As SOFIE, we’ll continue Zevacor Pharma’s commitment to customers, while making significant improvements to prepare us for growth as we help bring about the next generation of theranostics and tools to make and use them.”
A management team that includes Chief Revenue Officer Philipp Czernin, Chief Financial Officer Stan Berman, and Chief Technology Officer Melissa Moore will support Phelps.
Philipp Czernin, heading business development for the combined company, commented: “We’re looking to invest and improve the capabilities of the 16 sites to scale production of FDG and new products like Neuraceq for positron emitting tomography (PET) imaging of patients being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment, Netspot for localization of somatostatin receptor positive neuroendocrine tumors (NETs) using PET, 11C-Choline PET scans in those patients with biochemical failure from prostate cancer and negative anatomical imaging to restage the patient, and NaF PET scans for detection and evaluation of bone metastases.”
Melissa Moore, who will oversee operations for the commercial radiopharmacy and contract manufacturing organization, said: “With this acquisition, SOFIE will support the efforts of our academic and Pharma partners to help bring their novel diagnostics and therapeutics from early R&D through clinical trials and—hopefully—into routine clinical production. This is an amazing opportunity for us and our field.”
(Source: PR Newswire)
